Stockscreener 앱 받기
5.38
0.94%
0.05
시간 외 거래:
5.38
전일 마감가:
$5.33
열려 있는:
$5.32
하루 거래량:
112.40K
Relative Volume:
0.44
시가총액:
$303.49M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-4.0149
EPS:
-1.34
순현금흐름:
$-58.82M
1주 성능:
+0.56%
1개월 성능:
+13.26%
6개월 성능:
+33.50%
1년 성능:
+127.97%
1일 변동 폭
$5.245
$5.4437
1주일 범위
$5.21
$5.615
52주 변동 폭
$1.96
$6.91
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Almitas Capital LLC Has $4.20 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Frazier Life Sciences Management L.P. Takes Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Wall Street SWOT: Design Therapeutics stockInnovative approach in genetic disorder treatment - Investing.com
(DSGN) On The My Stocks Page - Stock Traders Daily
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock - Yahoo Finance
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming - The Bakersfield Californian
Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles - Business Wire
Halozyme Therapeutics And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
How to interpret Design Therapeutics Inc (DSGN)’s stock chart patterns - US Post News
Friedreich’s Ataxia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024-2034, estimated DelveInsight - Barchart
Initial in vivo validation of novel cancer therapeutics using AI - Drug Target Review
Designer brands director sells $145,640 in company stock - Investing.com
Progressive Ataxia And Weakness Disorders Market Segments, Drivers, Restraints, And Trends For 2024-2033 - EIN News
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day - Yahoo Finance
Designer Brands Inc’s latest rating changes from various analysts - Knox Daily
Short Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Decreases By 6.9% - MarketBeat
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - StockTitan
Let's Design a Trade Strategy on This Short-Squeezed, Low-Priced Stock - TheStreet
Financial Snapshot: Analyzing Designer Brands Inc (DBI)’s Key Ratio Metrics - The Dwinnex
Designer Brands Inc (NYSE:DBI) stock: You might be surprised - US Post News
Check Out Designer Brands Inc (DBI)’s Trade Data Rather Than the Analysts’ Views - SETE News
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
Acadian Asset Management LLC Has $1.95 Million Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Acadian Asset Management LLC Has $2.03 Million Stock Holdings in Geospace Technologies Co. (NASDAQ:GEOS) - Defense World
DSGN’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Analyzing DSGN’s price-to-book ratio for the last quarter - US Post News
DSGN stock soars to 52-week high, touches $5.52 - Investing.com
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - Marketscreener.com
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - StockTitan
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 4.4% - MarketBeat
Design Therapeutics Inc (DSGN) stock analysis: A comprehensive overview - US Post News
A new trading data show Design Therapeutics Inc (DSGN) is showing positive returns. - SETE News
Design Therapeutics, Inc. (NASDAQ:DSGN) Sees Large Drop in Short Interest - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Sees Large Drop in Short Interest - MarketBeat
North America Rare Disease Therapeutics Market Size, - GlobeNewswire
Psilera receives positive preclinical in vivo data for frontotemporal dementia (FTD) candidate, PSIL-006 - BioSpace
Psilera receives positive preclinical in vivo data for frontotemporal dementia (FTD) candidate, PSIL-006 - StreetInsider.com
Ocuphire Pharma (NASDAQ:OCUP) Stock Quotes, Forecast and News Summary - Benzinga
Design Therapeutics stock soars to 52-week high of $5.28 By Investing.com - Investing.com Australia
Design Therapeutics stock soars to 52-week high of $5.28 By Investing.com - Investing.com Canada
Design Therapeutics stock soars to 52-week high of $5.28 - Investing.com
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet - Yahoo Finance
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet - Nasdaq
Recent Insider Activity Could Benefit Design Therapeutics Inc (DSGN) - Knox Daily
Friedreich’s Ataxia Drugs Market is Projected to Reach US$ 3.49 Billion by 2034 | Fact.MR Report - GlobeNewswire
Friedreich’s Ataxia Drugs Market is Projected to Reach US$ 3.49 Billion by 2034 | Fact.MR Report - ForexTV.com
DSGN’s Q2 earnings predictions: What the experts say - US Post News
Vanguard Group Inc. Reduces Position in LL Flooring Holdings, Inc. (NYSE:LL) - Defense World
Vanguard Group Inc. Acquires 11,200 Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Price T Rowe Associates Inc. MD Makes New $45,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Global Access to Biotherapeutics | JustEvotec Biologics - Evotec
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):